APLS Overview
Upcoming Projects (APLS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (APLS)
-
Discussing the recent FDA approval of Apellis’ EMPAVELI® (pegcetacoplan) and the treatment landscape for patients 12 and older with IC-MPGN
Ticker: APLS
Executed On: Oct 09, 2025 at 01:15 PM EDT -
Quarterly Survey: Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Astellas’ Izervay July 2025
Tickers: APLS, ALPMF
Executed On: Jul 24, 2025 at 04:50 PM EDT -
A Second Look: Examining Kodiak Sciences Bi-Specific Clinical Pipeline for Non-Infectious Uveitis and Geographic Atrophy
Tickers: KOD, ALPMF, APLS, ABBV
Executed On: May 23, 2025 at 03:30 PM EDT -
Examining Kodiak Sciences Bi-Specific Clinical Pipeline for Non-Infectious Uveitis and Geographic Atrophy
Tickers: KOD, ALPMF, APLS, ABBV
Executed On: May 22, 2025 at 08:00 AM EDT -
Quarterly Survey: Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Astellas’ Izervay April 2025
Tickers: APLS, ALPMF
Executed On: Apr 23, 2025 at 05:15 PM EDT -
Discussing commercial use of Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay
Tickers: APLS, ALPMF
Executed On: Apr 10, 2025 at 02:30 PM EDT -
A Second Opinion: Discussing the use of Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay
Tickers: APLS, ALPMF
Executed On: Jan 27, 2025 at 04:00 PM EST -
Discussing the use of Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay
Tickers: APLS, ALPMF
Executed On: Jan 24, 2025 at 04:00 PM EST -
Quarterly Survey: Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Astellas’ Izervay January 2025
Tickers: APLS, ALPMF
Executed On: Jan 23, 2025 at 12:31 PM EST -
Discussing investigational agents for C3 glomerulopathy (C3G) including pegcetacoplan and iptacopan
Tickers: NVS, APLS
Executed On: Jan 15, 2025 at 03:30 PM EST -
Reviewing the Valeda System from Lumithera, a light-based therapy for geographic atrophy
Tickers: LUMITHERA, APLS, ALPMF
Executed On: Nov 22, 2024 at 03:00 PM EST -
A second look: Analyzing the Pivotal VALIANT Phase 3 Results for Pegcetacoplan in C3G and IC-MPGN from Apellis Pharmaceuticals (APLS)
Ticker: APLS
Executed On: Nov 20, 2024 at 10:00 AM EST -
Analyzing the Pivotal VALIANT Phase 3 Results for Pegcetacoplan in C3G and IC-MPGN from Apellis Pharmaceuticals (APLS)
Ticker: APLS
Executed On: Nov 08, 2024 at 04:30 PM EST -
Quarterly Survey: Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay October 2024
Tickers: APLS, ISEE
Executed On: Oct 22, 2024 at 11:59 AM EDT -
Analyzing the Phase 3 VALIANT Study Results for Pegcetacoplan in C3G and IC-MPGN from Apellis and Sobi
Tickers: APLS, SOBI.XSTO
Executed On: Sep 05, 2024 at 02:00 PM EDT -
Quarterly Survey: Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay July 2024
Tickers: APLS, ISEE
Executed On: Jul 23, 2024 at 02:12 PM EDT -
Quarterly Survey: Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay April 2024
Tickers: APLS, ISEE
Executed On: Apr 18, 2024 at 03:27 PM EDT -
Quarterly Survey: Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay January 2024
Tickers: APLS, ISEE
Executed On: Jan 23, 2024 at 04:40 PM EST -
Discussing the recent negative opinion from CHMP over Syfovre and the Geographic Atrophy Landscape with a European Retinal Specialist
Ticker: APLS
Executed On: Dec 20, 2023 at 08:00 AM EST -
Age-Related Macular Degeneration Treatment amidst FDA revised label for SYFOVRE (pegcetacoplan injection): A Deep Dive into Apellis Pharmaceuticals, Inc.'s Geographic Atrophy Treatment
Ticker: APLS
Executed On: Dec 12, 2023 at 12:00 PM EST -
A Second View: Checking in with a prescriber of Apellis' Syfovre in treating Geographic Atrophy (GA)
Ticker: APLS
Executed On: Nov 07, 2023 at 04:00 PM EST -
Checking in with a prescriber of Apellis' Syfovre in treating Geographic Atrophy (GA)
Ticker: APLS
Executed On: Nov 06, 2023 at 03:00 PM EST -
Quarterly Survey: Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay October 2023
Tickers: APLS, ISEE
Executed On: Oct 26, 2023 at 02:24 PM EDT -
Investigating the potential cause of Apellis' Syfovre's cases of occlusive retinal vasculitis with a focus on the images from the ASRS ReST committee report
Ticker: APLS
Executed On: Aug 11, 2023 at 02:00 PM EDT -
Quarterly Survey: Geographic Atrophy (GA) / Apellis' Syfovre and the impact of the Adverse Event Reports - July 2023
Tickers: APLS, ISEE
Executed On: Aug 01, 2023 at 03:28 PM EDT -
A Third Look: Understanding the impact of 6 reported cases of inflammation in patients receiving Syfovre injections
Tickers: APLS, ISEE
Executed On: Jul 20, 2023 at 03:00 PM EDT -
A Second Look: Understanding the impact of 6 reported cases of inflammation in patients receiving Syfovre injections
Tickers: APLS, ISEE
Executed On: Jul 19, 2023 at 04:00 PM EDT -
Understanding the impact of 6 reported cases of inflammation in patients receiving Syfovre injections
Tickers: APLS, ISEE
Executed On: Jul 18, 2023 at 09:00 AM EDT -
2 Week Delay: Apellis Pharmaceuticals' Pegcetacoplan GA Label and Pricing Individual Results
Tickers: APLS, ISEE
Executed On: Mar 13, 2023 at 05:39 PM EDT -
Discussing the use of MMRM analysis for the Apellis' DERBY and OAKS trial with a biostatistician
Ticker: APLS
Executed On: Oct 14, 2022 at 02:00 PM EDT -
A Second View: Digging into the topline data from Iveric Bio's Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophy and how it compares to Apellis' EMPAVELI
Tickers: ISEE, APLS
Executed On: Sep 09, 2022 at 01:30 PM EDT -
Digging into the topline data from Iveric Bio's Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophy
Tickers: ISEE, APLS
Executed On: Sep 07, 2022 at 04:30 PM EDT -
Discussing the 2-year results from Apellis' Phase 3 DERBY and OAKS Studies for EMPAVELI (pegcetacoplan) in Geographic Atrophy
Ticker: APLS
Executed On: Sep 01, 2022 at 08:15 AM EDT -
An international perspective on the potential of intravitreal pegcetacoplan in patients with geographic atrophy after Apellis announces longer-term data from DERBY and OAKS studies
Ticker: APLS
Executed On: May 18, 2022 at 09:00 AM EDT
Upcoming & Overdue Catalysts (APLS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (APLS)
-
Apellis (APLS) and Sobi Announce EU Approval of Aspaveli (pegcetacoplan) for Treatment of PNH
Tickers: APLS, SOBI.XSTO
Occurred on: Dec 15, 2021
Strategic Initiatives (APLS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
